Insider's sale of shares at a lower price may suggest belief in the stock's full valuation. However, this is a weak sign and doesn't definitively indicate their view on the stock's value. The lack of insider buying recently and history of sales make us cautious about the stock.
Columbus McKinnon's high P/E compared to the market appears justified due to expected earnings growth and potential EPS increase. This is anticipated to strongly support the share price, barring changes in circumstances.
BOFA •$オスカーヘルスインク A(OSCR.US)$BofA analyst Kevin Fischbeck downgraded Oscar Health to Neutral from Buy with a price target of $6, down from $12. The analyst sees greater medical loss ratio uncertainty into 2023. The industry is going to have to manage through the expiration of the expanded Affordable Care Act subsidies, Medicaid redeterminations and the result shift within the risk pool making it more difficult to price, Fischb...
コロンブス マッキノンに関するコメント
• $オスカーヘルスインク A(OSCR.US)$ BofA analyst Kevin Fischbeck downgraded Oscar Health to Neutral from Buy with a price target of $6, down from $12. The analyst sees greater medical loss ratio uncertainty into 2023. The industry is going to have to manage through the expiration of the expanded Affordable Care Act subsidies, Medicaid redeterminations and the result shift within the risk pool making it more difficult to price, Fischb...
• $アメリソース・バーゲン(ABC.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $182 (from $175)
• $アライメント ヘルスケア インク(ALHC.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $14 (from $18)
• $シグナ グループ(CI.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $300 (from $265)
• $カナディアン ナショナル レイルウェイ(CNI.US)$ : Evercore ISI Upgrades to Outperform from In Line
• $ヨウダオ(DAO.US)$ : Citic Securities Upgrades to Buy from Neut...
まだコメントはありません